Know Labs publishes peer-reviewed study showing 93.37% accuracy in non-invasive glycemic status classification

USBC, Inc.

Study in Diabetes Technology & Therapeutics: RF sensor and ML algorithm classified glycemic status with 93.37% accuracy vs. venous blood glucose.
31 participants with prediabetes or Type 2 diabetes; 2,637 paired observations from OGTT and control sessions.
Sensitivities: 96.63% for normoglycemic, 85.51% for hyperglycemic; no misclassification between hypo- and hyperglycemic extremes.
CEO Ron Erickson: proof-of-concept for non-invasive screening device to help identify undiagnosed diabetes in underserved populations.
Company maintains focus on FDA-cleared non-invasive CGM (KnowU); RoW screening product explored with partners.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.